Rife experts

Women with implantable cardioverter defibrillators fare less well than men

Publciado por rifeexperts - 30/01/10 a las 05:01:22 am

While ICDs - implantable cardioverter defibrillators - are the device of choice to on kinky heart rhythms, a new retreat led by cardiologists at the University of Pennsylvania Teach of Medication suggests that women with ICDs traveller less well than their man’s counterparts.

In a retrospective analysis to be presented at the AHA Scientific Sessions 2007 on Sunday, November 4 (Poster #C148; 3 p.m.), lead researcher Andrea Russo, M.D., Clinical Associate Professor of Medicine, suggests that despite the proven overall effectiveness of the devices, women had a greater risk of dying than men.

Using data from the completed INTRINSIC RV trial, the researchers compared results from 1237 men and 293 women. (The INTRINSIC RV trial, which was completed in 2006, compared dual- and single-chamber ICDs.)

“There is a paucity of data comparing outcome and arrhythmic events in men vs. women with ICDs,� said Dr. Russo, who is also Director of the Electrophysiology Laboratory at Penn Presbyterian Medical Center. “We chose the INTRINSIC RV study because it enrolled the largest total number of women.�

The researchers found that women with ICDs required hospitalization and had a higher mortality than men with the device. However, after adjusting for other factors, such as the presence of coronary artery disease, heart failure and medical treatment, these gender differences in outcome were no longer present.

According to Dr. Russo, this means that women may be sicker by the time they receive ICDs. In addition, women appear to be under-treated with medications such as beta-blockers and ACE inhibitors in this study. On the other hand, she notes, women appeared to be just as likely as men to receive appropriate shocks from their devices for abnormal rapid rhythms from the lower chamber of the heart.

“This research confirms the need for additional studies to learn why there is such a disparity between the sexes,� Dr. Russo says. “Then we also can learn which women will most benefit from the devices.�

In conclusion, the researchers postulate that the differences may be related to how aging and lifestyle factors affect women and men who receive ICDs. They recommend that additional research focus on gender differences among patients who receive implantable cardioverter defibrillators.

http://pennhealth.com

Ultra-Potent Antibody Motavizumab Is Safe After Second Season Of RSV Prophylaxis

Publciado por rifeexperts - 28/01/10 a las 08:01:27 am

The favorable refuge profile of the investigational enhanced potency anti-respiratory synctial virus (RSV) monoclonal antibody (MAb) motavizumab, when given for a right hand consecutive spice in shrill-risk children, is agreeing with that seen during the prime seasoned, advanced data indicate.

The findings, from a phase I/II haunt reported at the 45th Annual Meeting of the Infectious Diseases Society of America (IDSA), also pose that motavizumab is as safe as the treatment rod palivizumab (Synagis®).

“Respiratory synctial virus is a important source of lower respiratory infections among young children, with high rates of hospitalization seen in patients with chronic lung and congenital basics diseases,” said co-inventor Genevieve A. Losonsky, MD, vice-president, clinical development, infectious affliction, MedImmune, in Gaithersburg, Maryland.

“While prophylaxis of intoxicated-risk children with palivizumab is associated with an overall reduction in RSV hospitalization of about 50 percent and is unhurt and well tolerated, the development of unknown treatments that offer the potential concerning additional clinical benefits is superb.”

Dr. Losonsky shared findings in 136 infants who received at least three motavizumab doses in their first RSV pep up and were randomized to profit five monthly intramuscular injections of motavizumab or palivizumab 15 mg/kg in their second RSV mellow.

Participants in the inquiry were 24 months of seniority or less and were considered at high jeopardize of RSV because they were born at 35 weeks gestation or less or had chronic lung ailment because they were born prematurely.

Safety was assessed through 30 days after their fifth and decisive dose.

The two treatment groups were nearly the same with detail to baseline demographic and clinical characteristics.

Results showed that the degree and severity of adverse events was similar in motavizumab- and palivizumab-treated patients.

Specifically, the ponder found that 84.8 percent of the motavizumab group and 88.6 percent of the pavilizumab alliance knowing an adverse event (AE), with over 95 percent of all considered mild to mediate in both groups. Transient mild erythema at the injection situation was the most non-private dose-related AE in each group, occurring in 15.2 percent versus 11.4 percent of the two groups, mutatis mutandis.

Unsmiling AEs occurred in four (6.1 percent) patients in the motavizumab group, alone one of which was reflection to be possibly correlated to the think over treatment.

Anti-motavizumab binding activity was not detected during treatment through 90 to 120 days after the final quantity in any invalid who received motavizumab for a second RSV pep up.

In addition, motivizumab serum trough concentrations during a second salt of treatment were comparable to those achieved during the first condition.

“Based on our observations, it appears that motavizumab or palivizumab can be safely administered for a second consecutive RSV mature in high-risk patients who received motavizumab during their first RSV season,” Dr. Losonsky said.

To date, motavizumab has been shown to have clinical labour in preventing weighty RSV disease in maximum-jeopardize children in two efficacy trials. In a phase 3 whack that compared motavizumab and palivizumab, motavizumab demonstrated non-inferiority to palivizumab with a 26 percent relative reduction in the primary endpoint of RSV hospitalizations. In a placebo-controlled, phase 3 trial, motavizumab reduced RSV hospitalizations by 83 percent in pongy chief-risk Native American, full-title infants - a citizenry known to be at high risk of RSV hospitalizations.

By Jill Stein
Jill Stein is a Paris-based medical writer
Jillstein03 at cs.com

View drug report on Synagis.

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today

Some Congressional Democrats Promote Family Planning, Assistance For Women Proceeding With Unintended Pregnancies, Avoid Abortion Issue Directly

Publciado por rifeexperts - 26/01/10 a las 06:01:26 pm

The Washington Post on Sunday examined how Democratic congressional leaders are attempting to “tiptoe around the abortion issue” by calling for the approval of legislation that would assist women who carry unintended pregnancies to term and encourage contraception end. According to the Delivery, Forebears Orator Nancy Pelosi (D-Calif.) has “helped peaceful the path” for a regulate sponsored by Rep. Tim Ryan (D-Ohio), who opposes abortion rights, and Rep. Rosa DeLauro (D-Conn.), who supports abortion rights, that would expand access to contraception, extend adoption tax credits, boost health care access fitted low-takings women and children, and nest egg sex education programs. Senate Majority Leader Harry Reid (D-Nev.), who opposes abortion rights, has introduced a measure (S 21) that would increase access to emergency contraception, and increase subdivision planning services funding and guarantee contraception equity in health indemnity plans. The bills are an “attempt to broaden the chin-wag beyond the traditional framework of whether abortion should be legal,” and the moderate Democratic policy congregation Third Behaviour pattern has been giving counsel to lawmakers more “prevention rhetoric,” the Post reports. Some Democrats wish measures aimed at preventing unintended pregnancies will “become a bridge within the team and even across the aisle to some Republicans,” but there are “still minefields” in regard to the deliver, the Postal service reports. Democrats for the benefit of Life, which opposes abortion rights, does not keep Ryan and DeLauro’s measure. A substitute alternatively, the group is calling for second of a tabulation supported by some Republicans that would elaborate on health benefits and good health services for pregnant women and would improve fitness guarantee for prenatal care. The measure does not tabulate provisions on contraception (Murray, Washington Post, 1/21).

“Reprinted with franchise from http://www.kaisernetwork.org. You can view the unmixed Kaiser Diurnal Fitness Policy Report, search the archives, or sign up owing email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Common Health Policy Report is published for kaisernetwork.org, a free maintenance of The Henry J. Kaiser Family Foundation . © 2005 Advisory Accommodate Company and Kaiser Division Foundation. All rights reserved.

When it comes to low fat diets - all are not equal!

Publciado por rifeexperts - 24/01/10 a las 04:01:33 am

Trendy research from the Stanford University Kind of Medicine re-enforces what Keep something under one’s hat always told you, have a bite those veggies and those other nutrient-slow-witted foods because they’re good for you!

In yet more advice on what to eat and what not to eat, researchers have found that a low-fat diet rich in vegetables, fruits, whole grains and beans has twice the cholesterol-lowering power of a conventional low-fat diet, and even when meals contain the same amount of saturated fat and cholesterol a meal of spinach salad, egg and oatmeal-carrot cookies is healthier for your heart than stir-fried lean beef and asparagus and low-fat chocolate chip cookies. It was found that it is not enough to simply steer clear of saturated fat and cholesterol.

In a meticulous comparison of two low-fat diets, the conventional diet, focused solely on avoiding harmful saturated fat and cholesterol and diners ate such foods as frozen waffles and turkey bologna sandwiches, the other diet included the same proportions of fat and cholesterol, plus lots of plant-based foods in accordance with American Heart Association guidelines. Those diners ate such foods as hot grain cereals and vegetable soups.

Both diets lowered total and low-density lipoprotein (LDL, or “bad”) cholesterol over the course of the four-week study. The conventional diet produced, on average, a 4.6 percent LDL decrease. But the plant-based diet won hands-down as it achieved, on average, a 9.4 percent decrease in LDL. Researchers found no significant differences in changes in triglycerides or high-density lipoprotein (”good”) cholesterol and say that the effect of diet on lowering cholesterol has been minimized and undermined by a lot of clinicians and researchers.

Christopher Gardner, PhD, assistant professor (research) of medicine at the Stanford Prevention Research Center and lead author on the National Institutes of Health-funded study, says many doctors have felt better about putting patients on drugs to control cholesterol and part of the reason was that diets were not given a fair go as the focus was on the negative and what to avoid rather than on what to include.

Gardner says that it is hoped that people will appreciate the new American Heart Association Guidelines, and include more ‘whole grains and vegetables and beans and colours, not just iceberg lettuce, but red bell peppers and carrots and broccoli and red cabbage and the really colourful foods in their diet’ as they are all really low in saturated fat and cholesterol and very high in other nutrients and phytochemicals.

A “plant-based” diet is not a vegetarian diet but simply includes a basis of whole grains, vegetables, beans, nuts, seeds and fruits. The 2000 AHA guidelines recommend at least five daily servings of vegetables and fruits and at least six daily servings of grains with an emphasis on whole grains.

Gardner says other studies have also shown plant-based diets to be effective in lowering cholesterol.

The interesting aspect of the Stanford study is that it breaks new ground by comparing two patient groups eating different foods but identical amounts of total and saturated fat, protein, carbohydrate and cholesterol. So the two groups’ different levels of blood cholesterol change are attributable to the different foods — dark green salads and bean burritos, for example, versus iceberg lettuce and frozen pizza — and not differences in saturated fat and cholesterol intake.

The randomized clinical trial included 120 adults, ages 30 to 65 and all were members of the target population for food-based approaches to lowering cholesterol with moderately high LDL levels, between 130 and 190 mg/dL. They were randomly divided into two diners’ groups: 61 ate the conventional diet, while 59 ate the plant-based diet. Each weekday for a month, they visited a research dining hall for a specially prepared, carefully weighed, chemically analysed lunch or dinner.

The study required that participants maintain a constant weight so that any changes in blood cholesterol would be attributable to the diets themselves — not to any changes in weight brought on by the diets. When changes in weight were observed, the participants’ calories were changed accordingly to help them stay stable. In general researchers tended to add calories to the meal plan over the course of the study as participants were observed to be more likely to lose weight than to gain weight on both diets.

The scientists also requested that no one change exercise habits, saying: “If you are a marathon runner, keep running marathons. But if you’re a couch potato, we need you to stay a couch potato.”

Gardner, a 20-year vegetarian who specializes in nutrition and preventive medicine, expects a plant-based diet combined with weight loss and exercise to achieve even more impressive cholesterol-lowering results.

Gardner’s research collaborators include Ann Coulston; Lorraine Chatterjee; Alison Rigby, PhD, MPH; Gene Spiller, PhD, and John Farquhar, MD.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions — Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford.

The findings are published in the May 3 issue of the Annals of Internal Medicine.

http://mednews.stanford.edu

How to Get Rid of Pimples Fast - Know These Methods That Can Harm Your Family!

Publciado por rifeexperts - 21/01/10 a las 05:01:39 am

Recognising that acne is arguably the commonest condition worldwide, I’m perpetually amazed at the weight of inaccurate intelligence there is with how to get rid of pimples fast. While there are treatment notions that are passed down the generations, a lot of these are not validated by well-ordered or medical into. More disturbing is the imminent outcome of testing some of these choices.

Here is a number of popular pimple treatments which flatly do not work.

A. Squeezing your spots is generally not advisable in battling acne. Performing this will extend and propagate the acne to additional sections of the affected region.

B. Sellotape left overnight on one’s skin and taken out in the day will for certain take away stagnant skin cells along with surplus oil rapidly, although in all likelihood will harm the tender skin, and might lead to an allergic reaction to the glue.

C. Should you’ve acne and consume particular oral medications, suntanning as well as utilising a sun bed are possibly risky, not to mention not being beneficial for your pimples.

D. Home facial saunas will not do anything for your acne, but instead will worsen your skin that is already sensitive.

E. Home cleansing products, even when diluted, shouldn’t be utilised for acne care. This option has serious potential side effects, such as chemical burns.

F. Likewise cleansing powders along with washing fluid are useless for acne.

You should be aware that numerous unsuitable acne remedial options that regrettably worsen problematic skin of a lot of acne sufferers. Stay away from those shortcuts about how to get rid of pimples fast and follow a plan supervised by your doctor, or one that is supported by valid scientific and medical research. Practising this will steer you to success and you will soon bid farewell to acne.

Looking to learn more about how to eliminate acne? I have just finished a brand new guide, “Ultimate Guide to Non-Prescription Acne Treatment for Busy Mothers”

Grab it free here right now: http://ultimateguide.overthecounteracne.com/

Natural Yeast Infection Cures - Ladies Take Note, Here Are 3 Powerful Solutions

Publciado por rifeexperts - 18/01/10 a las 10:01:37 pm

If you want a health yeast infection cure, you indubitably identify all too famously the problems with unnatural cures. For joke, medications mould creams and vaginal suppositories not in any way quite get to the extirpate of the problem, they only purge things up temporarily. You have to save on heading to the trust in and using them each time you find yourself with a yeast infection. Not only that but some of these products undertaking horrible side effects even worse than the modify itself! In addition, there are many baleful chemicals in medications which you do not want to make a policy of using guts of your body. So what is the solution? Is there a realistic yeast infection remedy out there?

Well, one natural method you can try which is quite simple is vitamin B6 and C supplementation. Why vitamin supplementation? Well these vitamins work to enhance your immune system and we usually get yeast infections when our immune system has been compromised. Taking these vitamins is like treating a flu, you’re giving your body the nourishment it needs to fight off an infection, in this case a yeast infection.

Another thing to try is to wear more loose fitting clothes. When you wear tight jeans, you are creating a tight and congested space which is the perfect breeding grounds for yeast. You don’t necessarily have to wear some ill fitting jeans, you can simply wear a skirt.

Lastly, there is the ever popular yogurt treatment. By buying some sugar free yogurt and dipping a tampon into that, you’ve got a tampon coated in a naturally occurring bacteria that was designed to fight off fungii. Simply insert that into your vagina and the bacteria in the yogurt will get to work. If you’re finding it hard sliding it inside, try freezing it. It will also be cooling and alleviate some of the itching and burning.

When combined into 1 treatment plan, these 3 tips will help you, but if you want a natural yeast infection cure, you’re going to have to look for something which packs more punch.

Do you want us to unveil to you a powerful way to cure yeast infection?

If you’re tired of the itching, burning and swelling, and want an immediate fix, click here: Treatment For Yeast Infection

Delicate balance of induction and inhibition in determining tooth cusps

Publciado por rifeexperts - 16/01/10 a las 01:01:48 am

One of the remaining challenges for evolutionary developmental studies of mammals, whose evolution is best known from their teeth, is how their tooth shape is altered during development.

Researchers of the University of Helsinki together with their Japanese colleagues from the Kyoto University now propose a ‘balance of induction’ mechanism directing the placement of tooth shape features called cusps. Position and shape of cusps determine whether a tooth shape belongs to human or mouse, for example. Whereas developmental initiation of cusp formation is known to involve several developmental genes at the places of future cusps, it has remained unknown how cusps form at the right places.

Computer simulations on tooth development have suggested that there should be a gene inhibiting induction of cusps. The research team has now identified this inhibitor to be a recently identified gene called ectodin. It turned out that ectodin is the first gene that is expressed as a mirror image of the future cusps.

The team generated a mouse that has no functional ectodin. Whereas the mice appear fairly normal, the areas forming cusps were much broader resulting in cheek teeth whose shape resembles more rhinoceros teeth than mouse teeth. Furthermore, these mice have extra teeth and sometimes adjacent teeth are fused. These results indicate that there is a delicate balance of induction and inhibition in determining tooth cusps and that ectodin is a key gene in this developmental control.

The team confirmed the importasnce of ectodin to development of teeth by culturing teeth that produce ectodin and teeth that lack ectodin with excess amounts of cusp inducing protein (bone morphogenetic protein or BMP). Whereas teeth producing ectodin develop quite normally with excess BMP, teeth without ectodin had a markedly accelerated induction of cusps. Indeed the researchers were able to induce cusps and mineralization of teeth much faster than happens in normal mouse teeth, suggesting that tinkering with the balance of cusp induction may hold potential for future tissue engineering of hard tissues.

http://www.helsinki.fi/

The Best Snoring Solution Method

Publciado por rifeexperts - 13/01/10 a las 03:01:50 pm

I want to talk to you roughly the most appropriate snoring denouement method that you can take advantage of to help fix your uncontrollable. More and more people seem to be suffering from this problem and demand still to statue in default what they need to do about it. It’s surprising to realize that people go decade after decade with this problem and don’t even pilfer one free attempt at fixing it. I think this speaks volumes about the issue; the real mind-boggler. People don’t categorically know what to do when they have this predicament and they don’t assess to figure it minus either. This is why want to share with you the best snoring figuring out that you can use to fix this problem.

Snoring occurs because muscles go loose while you’re asleep. This includes the muscles that are in and around your throat area. There is a specific physics issue that happens when you have a lot of constriction around the throat area. What happens is that air will travel at a much asked to rate this creates a very violent type of vibration and that creates the sounds of snoring. That’s why you need to keep your mouth closed through at least held up to prevent snoring.

The best snoring solution that you can use is jaw supporter. It is a really simple device that is designed to support your jaw and keep it up. It is about the easiest device that you can use it as it takes around 5 seconds to put on. And another great feature of it is that it works the first night you apply it.

Learn more about how to Stop Snoring Forever

Joint effort means 750,000 of the world’s poor will have acess to TB drugs

Publciado por rifeexperts - 11/01/10 a las 12:01:55 am

Thanks to a partnership between the Earth Constitution Organisation (WHO) and an international initiative, anti-tuberculosis drugs will modern be available to people in on one’s uppers countries.

The deal between the Stop TB Partnership’s Global Drug Facility and UNITAID will deliver drugs and direct technical assistance, to more than three-quarters of a million people who otherwise would not receive treatment or might have their treatment interrupted because drugs were not available.

The project is restricted to anti-TB treatments suitable for people whose form of TB is not resistant to standard therapies, and means a stockpile of anti-TB drugs will be made available to countries facing shortages because of humanitarian emergencies or inadequate capacity for planning orders.

The $26.8 million initiative will ensure some 750,000 people in 19 countries, will have the cost of their anti-tuberculosis drug covered until 2008.

It will also provide drugs to countries expanding their TB control efforts who were promised support from the Global Fund to Fight AIDS, Tuberculosis and Malaria or another donor, but do not yet have the funds.

Experts believe TB and AIDS are the main health threats in Africa and say the two are closely linked, with victims of one often vulnerable to the other; a six-month course of treatment for TB costs $20.

Globally 8.8 million new cases and 1.6 million deaths occur from TB each year and left untreated, TB has the ability to develop into difficult to treat, drug-resistant strains.

According to Robert Matiru, operations manager of the Stop TB Partnership’s Global Drugs Facility, the drugs will come from four generics manufacturers, in India, Lupin, Cadila, Sandoz India and Svizera in Europe.

Dr. Marcos Espinal, of the Stop TB Partnership says getting anti-TB drugs to people who need them and making sure they complete their treatment is the best weapon in preventing drug-resistant TB.

The joint Global Drug Facility/UNITAID project will provide first-line TB drugs to Bangladesh, Bosnia and Herzegovina, Burkina Faso, Cameroon, Cote d’Ivoire, Guinea, Iraq, Kenya, Madagascar, Mali, Mozambique, Myanmar, Niger, Nigeria, Rwanda, Tajikistan, The Gambia, Togo and Uganda.

The Global Drug Facility is the drug supply arm of the Stop TB Partnership and provides countries with the drugs, technical assistance and supplies needed to diagnose and treat adults and children with both drug-sensitive and drug-resistant TB.

The Stop TB Partnership, hosted by WHO is a network of more then 500 international organizations, countries, patient groups, donors from the public and private sectors, and nongovernmental and governmental organizations that are working together to eliminate TB.

The UNITAID initiative was launched in September 2006 by Brazil, Chile, France, Norway and the United Kingdom and aims to contribute to the scale-up of treatment in developing countries for HIV/AIDS, malaria and tuberculosis by reducing the price of quality drugs and diagnostics and to accelerate the pace at which they are made available by mobilizing innovative financing mechanisms.

Antipsychotic drugs get FDA label changes

Publciado por rifeexperts - 08/01/10 a las 01:01:00 am

The U.S. Nourishment and Drug Direction today exercised its unripe sage care of the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of “conventional” antipsychotic drugs to flatter safety-related changes to prescribing information, or labeling, to apprise about an increased risk of end associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

In 2005, the FDA announced similar labeling changes for “atypical” antipsychotic drugs. At that time, Boxed Warnings, the FDA’s strongest, were added. The Boxed Warning will now be added to an older class of drugs known as “conventional” antipsychotics. The warning for both classes of drugs will say that clinical studies indicate that antipsychotic drugs of both types are associated with an increased risk of death when used in elderly patients treated for dementia-related psychosis.

“It is important that health care professionals and consumers have the most up-to-date drug safety information,” said Thomas Laughren, M.D., director of the FDA’s Division of Psychiatry Products in the Center for Drug Evaluation and Research. “The prescribing information for all antipsychotic drugs will be updated to describe the risk of death in elderly patients being treated for symptoms associated with dementia.”

Antipsychotic drugs commonly are categorized into two classes, the older “conventional” antipsychotics and the newer “atypical” antipsychotics. Both classes of drugs are dopamine receptor antagonists that work by blocking the action of naturally occurring dopamine in the brain. They differ primarily in their side effects, with the atypical drugs having a lower incidence of neurological side effects such as involuntary movements or “tics.”

Neither class of antipsychotic is FDA-approved for use in the treatment of dementia-related symptoms, which can include forgetfulness, poor memory, and an inability to recognize familiar objects, sounds, or people. The drugs are FDA-approved primarily for the treatment of symptoms associated with schizophrenia. The decision to use antipsychotic medications in the treatment of patients with symptoms of dementia is left to the discretion of the physician. Such use is often called “off-label” use and falls within the practice of medicine.

Recently, two observational epidemiological studies were published that examined the risk of death in elderly patients with dementia who were treated with conventional antipsychotic drugs. The investigators compared the risk for death with use of an atypical antipsychotic versus either no antipsychotic or the use of a conventional antipsychotic. These studies have limitations that preclude reaching a definitive conclusion about comparative death rates for atypical and conventional antipsychotic drugs. Nevertheless, the FDA has concluded that these studies, along with the earlier evidence for atypical antipsychotic drugs, suggest that both classes of drugs should be considered to have an increased risk of death when used in elderly patients treated for dementia-related psychosis.

An explanation of the data and advice for treating patients is available in an FDA notice to health care professionals being issued today.

The FDA today issued letters to the manufacturers of both types of antipsychotic drugs, under the new authority of FDAAA, notifying the manufacturers that they should make changes to drug labeling. Manufacturers of both classes of drugs are being asked to change labeling so that all of the drugs carry uniform warning language. Manufacturers of these drugs are required to submit new language to the FDA within 30 days, or to provide a reason why they do not believe such labeling changes are necessary. If they do not submit new language, FDAAA provides strict timelines for resolving the issue and allows the agency to initiate an enforcement action if necessary.

People taking antipsychotic drugs should not abruptly stop taking them. Caregivers and patients should talk to the patient’s health care professionals about any concerns.

The medications involved in this action are:

Conventional Antipsychotic Drugs

Compazine (prochlorperazine)
Haldol (haloperidol)
Loxitane (loxapine)
Mellaril (thioridazine)
Moban (molindrone)
Navane (thithixene)
Orap (pimozide)
Prolixin (fluphenazine)
Stelazine (trifluoperazine)
Thorazine (chlorpromazine)
Trilafon (perphenazine)

Atypical Antipsychotics

Abilify (aripiprazole)
Clozaril (clozapine)
FazaClo (clozapine)
Geodon (ziprasidone)
Invega (paliperidone)
Risperdal (risperidone)
Seroquel (quetiapine)
Zyprexa (olanzapine)
Symbyax (olanzapine and fluoxetine)

For more information, see

FDA Information for Healthcare Professionals: Antipsychotics

FDA Historical Information on Atypical Antipsychotic Drugs

http://www.fda.gov

Buscar

Este Sitio web está bajo licencia Creative Commons Attribution 3.0 License